Posted by Michael Wonder on 30 Jul 2024
Vertex announces FDA acceptance of new drug application for suzetrigine for the treatment of moderate to severe acute pain
30 July 2024 - FDA grants priority review and assigns a PDUFA target action date of 30 January 2025.
Vertex Pharmaceuticals today announced that the US FDA has accepted its new drug application submission for suzetrigine, an investigational, oral, selective NaV1.8 pain signal inhibitor to treat moderate to severe acute pain.
